2023 North America Conference on Lung Cancer (NACLC) - Posters and Abstracts-PP01.002 Antonious Hazim Abstract

PP01.002 Antonious Hazim Abstract

Pdf Summary

This study examined the clinical characteristics and outcomes of patients with EGFR-mutated non-small cell lung cancer (NSCLC) who were treated with EGFR targeted therapy followed by immunotherapy (IO). The researchers conducted a retrospective review of patients at their institution between January 2014 and December 2022.<br /><br />The study included 59 patients with EGFR-mutated NSCLC, with a median age of 61. At initial diagnosis, 76% had Stage IV disease and 37% had central nervous system metastasis. The EGFR mutations identified included Exon 19 deletions, Exon 21 (L858R), T790M, Exon 18 G719A, and others.<br /><br />The median overall survival (OS) for the entire cohort was 41 months. Most patients received osimertinib as their initial EGFR therapy. Median progression-free survival (PFS) on initial EGFR therapy was 13 months. About half of the patients received a second EGFR TKI with a median PFS of 14 months. Patients who received two EGFR TKIs had a significantly longer median OS compared to those who did not receive a second TKI.<br /><br />Among the patients who received IO, 85% underwent concurrent chemotherapy. The median PFS of IO with chemotherapy was 5 months. Patients receiving IO with chemotherapy had a longer median PFS compared to those who only received IO.<br /><br />The researchers concluded that patients treated with IO monotherapy after progressing on EGFR TKI did not show durable treatment response compared to those receiving combination chemoimmunotherapy. This suggests a benefit from cytotoxic agents in this clinical context.<br /><br />In summary, this study highlights the clinical characteristics and outcomes of patients with EGFR-mutated NSCLC treated with sequential EGFR targeted therapy and immunotherapy. The findings suggest the potential benefits of combination chemoimmunotherapy in this patient population.

Keywords

EGFR-mutated non-small cell lung cancer

EGFR targeted therapy

immunotherapy

retrospective review

Stage IV disease

central nervous system metastasis

osimertinib

progression-free survival

EGFR TKI

chemoimmunotherapy